Primary endpoint of change from baseline on adapted Mayo Score for CBP-307 0.2 mg once-daily, orally administered dose showed a numerical improvement, but did not achieve statistical significance
Clinical Remission on adapted Mayo Score and other secondary endpoints achieved statistical significance with strong evidence of pharmacodynamic activity as measured by reduction in lymphocyte counts, and CBP-307 was observed to be generally well tolerated
Company intends to engage in partnership discussions for future development of CBP-307 to focus on lead program CBP-201 (IL4R antagonist)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.